Development of [18F]Maleimide-Based Glycogen Synthase Kinase-3β Ligands for Positron Emission Tomography Imaging.

Dysregulation of glycogen synthase kinase-3β (GSK-3β) is implicated in the pathogenesis of neurodegenerative and psychiatric disorders. Thus, development of GSK-3β radiotracers for positron emission tomography (PET) imaging is of paramount importance, because such a noninvasive imaging technique would allow better understanding of the link between the activity of GSK-3β and central nervous system disorders in living organisms, and it would enable early detection of the enzyme's aberrant activity. Herein, we report the synthesis and biological evaluation of a series of fluorine-substituted maleimide derivatives that are high-affinity GSK-3β inhibitors. Radiosynthesis of a potential GSK-3β tracer [18F]10a is achieved. Preliminary in vivo PET imaging studies in rodents show moderate brain uptake, although no saturable binding was observed in the brain. Further refinement of the lead scaffold to develop potent [18F]-labeled GSK-3 radiotracers for PET imaging of the central nervous system is warranted.

[1]  Steven H. Liang,et al.  Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. , 2016, Angewandte Chemie.

[2]  Jen Q. Pan,et al.  Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. , 2016, ACS chemical biology.

[3]  Allen F. Brooks,et al.  Synthesis and evaluation of 4-[18F]fluorophenacylbromide (4FPB), a selective and irreversible inhibitor of Glycogen Synthase Kinase 3β (GSK-3 β) , 2016 .

[4]  M. Pandey,et al.  Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging , 2016, Theranostics.

[5]  Ming-Rong Zhang,et al.  Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3β (GSK-3β) inhibitors containing [(11)C]methylsulfanyl, [(11)C]methylsulfinyl or [(11)C]methylsulfonyl groups. , 2015, Bioorganic & medicinal chemistry letters.

[6]  G. Koning,et al.  A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[7]  Young T. Hong,et al.  Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3. , 2015, ACS medicinal chemistry letters.

[8]  Julio Caballero,et al.  Insights into the Interactions between Maleimide Derivates and GSK3β Combining Molecular Docking and QSAR , 2014, PloS one.

[9]  X. Shao,et al.  Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). , 2014, Nuclear medicine and biology.

[10]  Dani Brunner,et al.  Characterization of maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitors as stimulators of steroidogenesis. , 2013, Journal of medicinal chemistry.

[11]  C. Pérez,et al.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. , 2013, ACS chemical neuroscience.

[12]  B. Schmidt,et al.  Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models , 2012, International journal of Alzheimer's disease.

[13]  Alan A. Wilson,et al.  Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation. , 2012, Bioorganic & medicinal chemistry letters.

[14]  J. Beaulieu,et al.  Molecular Neuroscience Review Article Gsk-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder , 2022 .

[15]  James Robert Woodgett,et al.  Molecular Neuroscience Review Article Gsk-3: Functional Insights from Cell Biology and Animal Models , 2022 .

[16]  Jen Q. Pan,et al.  AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice , 2011, Neuropsychopharmacology.

[17]  Manuela G. López,et al.  The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice. , 2011, The journal of pain : official journal of the American Pain Society.

[18]  G. Hutchins,et al.  The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). , 2011, Bioorganic & medicinal chemistry letters.

[19]  Jesús Avila,et al.  Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors , 2010, Expert review of neurotherapeutics.

[20]  G. Peltz,et al.  Discovery of potent and bioavailable GSK-3beta inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[21]  A. Kozikowski,et al.  From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. , 2009, Journal of medicinal chemistry.

[22]  Jia Luo,et al.  Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.

[23]  Nicholas J Long,et al.  Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. , 2008, Angewandte Chemie.

[24]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[25]  T. Engler,et al.  Orally Bioavailable GSK‐3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo , 2006 .

[26]  Alan A. Wilson,et al.  Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. , 2005, Bioorganic & medicinal chemistry letters.

[27]  G. Dorn,et al.  Protein kinase cascades in the regulation of cardiac hypertrophy. , 2005, The Journal of clinical investigation.

[28]  R. Campbell,et al.  Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. , 2004, Journal of medicinal chemistry.

[29]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[30]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[31]  S. Knapp,et al.  Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.

[32]  Kirk W. Johnson,et al.  Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. , 2003, Diabetes.

[33]  Ana Martínez,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[34]  H. Eldar-Finkelman,et al.  Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[35]  P. Cohen,et al.  The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.

[36]  M. Saunders,et al.  3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). , 2001, Bioorganic & medicinal chemistry letters.

[37]  J. Woodgett,et al.  Glycogen Synthase Kinase-3β Is a Negative Regulator of Cardiomyocyte Hypertrophy , 2000, The Journal of cell biology.

[38]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[39]  E. Krebs,et al.  Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. , 1999, Diabetes.

[40]  M. Faul,et al.  A New, Efficient Method for the Synthesis of Bisindolylmaleimides. , 1998, The Journal of organic chemistry.

[41]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.